JPWO2020198009A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020198009A5 JPWO2020198009A5 JP2021556753A JP2021556753A JPWO2020198009A5 JP WO2020198009 A5 JPWO2020198009 A5 JP WO2020198009A5 JP 2021556753 A JP2021556753 A JP 2021556753A JP 2021556753 A JP2021556753 A JP 2021556753A JP WO2020198009 A5 JPWO2020198009 A5 JP WO2020198009A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 165
- 239000000427 antigen Substances 0.000 claims description 104
- 102000036639 antigens Human genes 0.000 claims description 104
- 108091007433 antigens Proteins 0.000 claims description 104
- 102000025171 antigen binding proteins Human genes 0.000 claims description 31
- 108091000831 antigen binding proteins Proteins 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 108060006698 EGF receptor Proteins 0.000 claims description 19
- 102000001301 EGF receptor Human genes 0.000 claims description 19
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 102000045108 human EGFR Human genes 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims description 4
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims description 4
- 201000001528 bladder urothelial carcinoma Diseases 0.000 claims description 4
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 4
- 201000003908 endometrial adenocarcinoma Diseases 0.000 claims description 4
- 208000029382 endometrium adenocarcinoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000006972 gastroesophageal adenocarcinoma Diseases 0.000 claims description 4
- 201000006974 gastroesophageal cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 229940125644 antibody drug Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 108060003951 Immunoglobulin Proteins 0.000 description 14
- 102000018358 immunoglobulin Human genes 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024131936A JP2024160318A (ja) | 2019-03-22 | 2024-08-08 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962822124P | 2019-03-22 | 2019-03-22 | |
| US62/822,124 | 2019-03-22 | ||
| PCT/US2020/023857 WO2020198009A1 (en) | 2019-03-22 | 2020-03-20 | EGFR x CD28 MULTISPECIFIC ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131936A Division JP2024160318A (ja) | 2019-03-22 | 2024-08-08 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526764A JP2022526764A (ja) | 2022-05-26 |
| JPWO2020198009A5 true JPWO2020198009A5 (enrdf_load_stackoverflow) | 2023-03-29 |
| JP7659501B2 JP7659501B2 (ja) | 2025-04-09 |
Family
ID=70228885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556753A Active JP7659501B2 (ja) | 2019-03-22 | 2020-03-20 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
| JP2024131936A Pending JP2024160318A (ja) | 2019-03-22 | 2024-08-08 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131936A Pending JP2024160318A (ja) | 2019-03-22 | 2024-08-08 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
Country Status (18)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020025926A2 (pt) * | 2018-06-21 | 2021-03-23 | Regeneron Pharmaceuticals, Inc. | anticorpos biespecíficos anti-psma x anti-cd28 e usos dos mesmos |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| CA3196726A1 (en) * | 2020-10-30 | 2022-05-05 | Janux Therapeutics, Inc. | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| WO2022096536A1 (en) * | 2020-11-03 | 2022-05-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies |
| US20220241328A1 (en) | 2021-01-11 | 2022-08-04 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| AU2023223455A1 (en) | 2022-02-23 | 2024-08-29 | Janssen Biotech, Inc. | Anti-cd28 x anti-psma antibodies |
| CN119233993A (zh) | 2022-03-07 | 2024-12-31 | 诺夫免疫股份有限公司 | 用于靶向t细胞活化的cd28双特异性抗体 |
| JP2025509702A (ja) | 2022-03-14 | 2025-04-11 | ラムキャップ バイオ ガンマ エージー | ＧＰＣ３陽性悪性細胞を標的殺傷するための二重特異性ＧＰＣ３ｘＣＤ２８抗体およびＧＰＣ３ｘＣＤ３抗体ならびにそれらの組み合わせ |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| TW202405015A (zh) * | 2022-04-11 | 2024-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｐｓｍａ和ｃｄ２８的抗原結合分子及其醫藥用途 |
| WO2023198042A1 (zh) * | 2022-04-11 | 2023-10-19 | 江苏恒瑞医药股份有限公司 | 特异性结合egfr和cd28的抗原结合分子及其医药用途 |
| AU2023308171A1 (en) | 2022-07-13 | 2025-01-23 | Regeneron Pharmaceuticals, Inc. | Mild acid immunoassays for detection of analytes |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| AU2023356866A1 (en) | 2022-10-03 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies |
| WO2024084052A1 (en) | 2022-10-21 | 2024-04-25 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| WO2024237744A1 (ko) * | 2023-05-18 | 2024-11-21 | 서울대학교산학협력단 | 항-cd40l/항-cd28 이중 특이 항체 및 이의 용도 |
| TW202519559A (zh) | 2023-07-10 | 2025-05-16 | 美商再生元醫藥公司 | 雙特異性PD-L1xCD28抗體及其使用方法 |
| WO2025026356A1 (zh) * | 2023-07-31 | 2025-02-06 | 百奥泰生物制药股份有限公司 | 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US8236308B2 (en) * | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| WO2007143168A2 (en) | 2006-06-02 | 2007-12-13 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| RS59001B1 (sr) | 2010-02-08 | 2019-08-30 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
| ES2628075T3 (es) | 2011-12-19 | 2017-08-01 | Synimmune Gmbh | Molécula de anticuerpo biespecífica |
| TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN104558190B (zh) | 2015-01-06 | 2018-08-10 | 中国药科大学 | 一种全人源靶向EGFR/KDR的IgG样双特异性抗体 |
| SMT202200050T1 (it) | 2015-09-23 | 2022-03-21 | Regeneron Pharma | Anticorpi bispecifici anti-cd3 ottimizzati e loro usi |
| ES2925563T3 (es) | 2016-09-23 | 2022-10-18 | Regeneron Pharma | Anticuerpos anti-MUC16 (Mucina 16) |
| CA3037732A1 (en) | 2016-09-23 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| KR20210104836A (ko) * | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도 |
-
2020
- 2020-03-20 EA EA202192566A patent/EA202192566A1/ru unknown
- 2020-03-20 MY MYPI2021005486A patent/MY209363A/en unknown
- 2020-03-20 PH PH1/2021/552300A patent/PH12021552300A1/en unknown
- 2020-03-20 JP JP2021556753A patent/JP7659501B2/ja active Active
- 2020-03-20 EP EP20718108.2A patent/EP3941941A1/en active Pending
- 2020-03-20 KR KR1020217032287A patent/KR20210142659A/ko active Pending
- 2020-03-20 CN CN202080022975.8A patent/CN113661177B/zh active Active
- 2020-03-20 BR BR112021018442A patent/BR112021018442A2/pt unknown
- 2020-03-20 SG SG11202110341WA patent/SG11202110341WA/en unknown
- 2020-03-20 MX MX2021011500A patent/MX2021011500A/es unknown
- 2020-03-20 AU AU2020247803A patent/AU2020247803A1/en active Pending
- 2020-03-20 US US16/825,179 patent/US11912767B2/en active Active
- 2020-03-20 WO PCT/US2020/023857 patent/WO2020198009A1/en active IP Right Grant
- 2020-03-20 MA MA055363A patent/MA55363A/fr unknown
- 2020-03-20 CA CA3134335A patent/CA3134335A1/en active Pending
-
2021
- 2021-09-19 IL IL286536A patent/IL286536A/en unknown
- 2021-09-21 CL CL2021002446A patent/CL2021002446A1/es unknown
- 2021-10-21 CO CONC2021/0014076A patent/CO2021014076A2/es unknown
-
2023
- 2023-02-07 US US18/165,515 patent/US20230322927A1/en active Pending
- 2023-09-21 CL CL2023002805A patent/CL2023002805A1/es unknown
-
2024
- 2024-08-08 JP JP2024131936A patent/JP2024160318A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020198009A5 (enrdf_load_stackoverflow) | ||
| US11673952B2 (en) | Antibodies specific to delta 1 chain of T cell receptor | |
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| Ko et al. | Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer | |
| CA2560305A1 (en) | Human anti-epidermal growth factor receptor antibody | |
| US9884910B2 (en) | Anti-PDGF-C antibodies | |
| CN105209493A (zh) | 用于诊断和治疗用途的her3特异性单克隆抗体 | |
| JPWO2020135201A5 (enrdf_load_stackoverflow) | ||
| US20200354460A1 (en) | Bispecific antibodies against EGFR and PD-1 | |
| RU2019104980A (ru) | Анти-icos антитела | |
| CN114761433B (zh) | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 | |
| WO2020018354A1 (en) | Bispecific antibodies targeting immune checkpoints | |
| TW202200620A (zh) | 抗flt3抗體及組合物 | |
| WO2018182420A1 (en) | Antibodies for the treatment of erbb-2/erbb-3 positive tumors | |
| CN115210261A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| CN112041346A (zh) | 用于与抗pd-1抗体组合的抗cd137抗体 | |
| RU2761638C1 (ru) | Антитела против лиганда программируемой смерти (pd-l1) и их применение | |
| JPWO2022061098A5 (enrdf_load_stackoverflow) | ||
| US20240156870A1 (en) | Anti-egfr single domain antibodies and therapeutic constructs | |
| WO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| CN118139884A (zh) | 人源化抗clec-1a抗体和其抗原结合片段及其模拟物 | |
| JP2022512628A (ja) | Ｃｄ１３７を標的とする抗体およびその使用方法 | |
| CN114573704B (zh) | Pd-1/ctla-4结合蛋白及其医药用途 | |
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела | |
| TH2101000290A (th) | องค์ประกอบของแอนติ-cd112r และวิธีการ |